Our state-of-the-art models, including patient-specific iPSC-derived cells, overexpression of wild-type or mutant ?-synuclein, and primary cultures, offer a robust platform for scientists to delve into the fundamental mechanisms of PD, screen potential drug candidates, and study the progression of the disease.
